Artiva Biotherapeutics, Inc.
Every calculator, already run for ARTV
Open the full toolkit →You have the numbers on ARTV. Get the argument.
A written report on which of these readings actually decide the outcome for Artiva Biotherapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering ARTVAnalyst Price Target Disagreement for Artiva Biotherapeutics, Inc.
Wall Street's bull case implies +248% from the current price; the bear case implies +95%. A 153% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2…
ARTV — frequently asked
Is ARTV a buy right now?
Wall Street's consensus rating on Artiva Biotherapeutics, Inc. is Strong Buy across 6 analysts, with a mean price target of $35.80 (+204% vs. the current $11.78). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Artiva Biotherapeutics, Inc.?
Analysts covering Artiva Biotherapeutics, Inc. (ARTV) range from a bear-case target of $23.00 to a bull-case high of $41.00, with a mean consensus target of $35.80 across 5 analysts. The spread of $18.00 (153% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Artiva Biotherapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Artiva Biotherapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARTV research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Artiva Biotherapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.